Anika Therapeutics ANIK Non-cash consideration and earn-out receivable from divestiture
Non-cash consideration and earn-out receivable from divestiture at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1.
The official record: Anika Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's non-cash consideration and earn-out receivable from divestiture.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's non-cash consideration and earn-out receivable from divestiture?
- Anika Therapeutics (ANIK) reported non-cash consideration and earn-out receivable from divestiture of $0 in Q4 2025.
- How has Anika Therapeutics's non-cash consideration and earn-out receivable from divestiture changed year-over-year?
- Anika Therapeutics's non-cash consideration and earn-out receivable from divestiture decreased by 100.0% year-over-year, from $1.48M to $0.
- What does non-cash consideration and earn-out receivable from divestiture mean?
- This represents the portion of consideration received from a divestiture that is not in the form of cash, such as equity, notes, or earn-out agreements. It provides insight into the structure of corporate restructuring deals and the potential for future cash inflows or risks associated with the divested assets. Investors use this to assess the quality and certainty of proceeds from asset sales.